Semaglutide Tested in Alcohol Use Disorder - Summary - MDSpire
From the Journals

Semaglutide Tested in Alcohol Use Disorder

Randomized trial found improvements in alcohol consumption and metabolic outcomes, with gastrointestinal adverse events more common with treatment

  • By

  • Kathryn Wighton

  • May 6, 2026

  • 5 min

Share

A randomized clinical trial published in The Lancet shows that weekly semaglutide significantly reduces heavy drinking days among patients with alcohol use disorder and obesity. Conducted in Denmark with 108 participants, the trial revealed reductions in heavy drinking days by 41 percentage points for semaglutide compared to 26 for placebo. Additionally, improvements were noted in total alcohol consumption, alcohol cravings, and metabolic markers. Lead author, Dr. Mette Kruse Klausen, emphasizes the potential of glucagon-like peptide-1 receptor agonists in treating alcohol use disorder.

Original Source(s)

Semaglutide Tested in Alcohol Use Disorder

  • by Kathryn Wighton

  • May 6, 2026

Related Content

Psilocybin for Cocaine Use: Signal or Noise?

Pilot randomized study suggests possible benefit, but blinding concerns and limited generalizability complicate interpretation

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.

AI Platform Linked to Modest Anxiety Improvements

Randomized trial shows small symptom reductions vs group therapy and control, with outcomes shaped by worsening scores in comparator arms